Modulating effect of lonidamine on response to doxorubicin in metastatic breast cancer patients: Results front a multicenter prospective randomized trial

Dino Amadori, Giovanni Luca Frassineti, Andrea De Matteis, Giorgio Mustacchi, Antonio Santoro, Salvatore Cariello, Massimo Ferrari, Ottorino Nascimben, Oriana Nanni, Alessandra Lombardi, Emanuela Scarpi, Wainer Zoli

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Previous results from our preclinical studies have shown that lonidamine (LND) can positively modulate the antiproliferative activity of doxorubicin (DOX) on breast cancer cell lines. To evaluate the effect of LND in a clinical setting, a multicenter randomized trial was carried out on patients with advanced breast cancer. From September 1991 to July 1993, 181 patients were enrolled in the trial and received an initial treatment of DOX at 75 mg/m2 for 3 cycles. The 137 patients who reached complete remission, partial remission, or stable disease were randomized to receive either DOX alone (75 mg/m2 day 1) (arm A) or DOX plus LND (600 mg orally/day) (arm B). The patients enrolled in the two arms were fairly homogeneous in terms of major clinical characteristics. Toxicity was similar in both arms except for myalgia: WHO grade ≤ 2 was observed in 57% of arm B patients. Overall response rate to DOX+LND was 50% and to DOX alone 38% in evaluable patients, and 48% vs 37% in all registered patients, as determined by an intention-to-treat analysis. The differences did not reach statistical significance. Conversely, in agreement with previous findings, we observed a significant difference in response rate in the subgroup of patients with liver metastases, regardless of the extent of hepatic involvement (DOX+LND 68% vs DOX 33%, p = 0.03). This observation makes LND an important tool in association with anthracyclines in the treatment of this subgroup of patients.

Original languageEnglish
Pages (from-to)209-217
Number of pages9
JournalBreast Cancer Research and Treatment
Volume49
Issue number3
DOIs
Publication statusPublished - 1998

Fingerprint

Doxorubicin
Breast Neoplasms
lonidamine
Intention to Treat Analysis
Liver
Anthracyclines
Myalgia
Multicenter Studies
Neoplasm Metastasis
Cell Line
Therapeutics

Keywords

  • Advanced breast cancer
  • Doxorubicin
  • Lonidamine

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Modulating effect of lonidamine on response to doxorubicin in metastatic breast cancer patients : Results front a multicenter prospective randomized trial. / Amadori, Dino; Frassineti, Giovanni Luca; De Matteis, Andrea; Mustacchi, Giorgio; Santoro, Antonio; Cariello, Salvatore; Ferrari, Massimo; Nascimben, Ottorino; Nanni, Oriana; Lombardi, Alessandra; Scarpi, Emanuela; Zoli, Wainer.

In: Breast Cancer Research and Treatment, Vol. 49, No. 3, 1998, p. 209-217.

Research output: Contribution to journalArticle

Amadori, Dino ; Frassineti, Giovanni Luca ; De Matteis, Andrea ; Mustacchi, Giorgio ; Santoro, Antonio ; Cariello, Salvatore ; Ferrari, Massimo ; Nascimben, Ottorino ; Nanni, Oriana ; Lombardi, Alessandra ; Scarpi, Emanuela ; Zoli, Wainer. / Modulating effect of lonidamine on response to doxorubicin in metastatic breast cancer patients : Results front a multicenter prospective randomized trial. In: Breast Cancer Research and Treatment. 1998 ; Vol. 49, No. 3. pp. 209-217.
@article{6f4e0c307b884a479dd0a81ec7eaa501,
title = "Modulating effect of lonidamine on response to doxorubicin in metastatic breast cancer patients: Results front a multicenter prospective randomized trial",
abstract = "Previous results from our preclinical studies have shown that lonidamine (LND) can positively modulate the antiproliferative activity of doxorubicin (DOX) on breast cancer cell lines. To evaluate the effect of LND in a clinical setting, a multicenter randomized trial was carried out on patients with advanced breast cancer. From September 1991 to July 1993, 181 patients were enrolled in the trial and received an initial treatment of DOX at 75 mg/m2 for 3 cycles. The 137 patients who reached complete remission, partial remission, or stable disease were randomized to receive either DOX alone (75 mg/m2 day 1) (arm A) or DOX plus LND (600 mg orally/day) (arm B). The patients enrolled in the two arms were fairly homogeneous in terms of major clinical characteristics. Toxicity was similar in both arms except for myalgia: WHO grade ≤ 2 was observed in 57{\%} of arm B patients. Overall response rate to DOX+LND was 50{\%} and to DOX alone 38{\%} in evaluable patients, and 48{\%} vs 37{\%} in all registered patients, as determined by an intention-to-treat analysis. The differences did not reach statistical significance. Conversely, in agreement with previous findings, we observed a significant difference in response rate in the subgroup of patients with liver metastases, regardless of the extent of hepatic involvement (DOX+LND 68{\%} vs DOX 33{\%}, p = 0.03). This observation makes LND an important tool in association with anthracyclines in the treatment of this subgroup of patients.",
keywords = "Advanced breast cancer, Doxorubicin, Lonidamine",
author = "Dino Amadori and Frassineti, {Giovanni Luca} and {De Matteis}, Andrea and Giorgio Mustacchi and Antonio Santoro and Salvatore Cariello and Massimo Ferrari and Ottorino Nascimben and Oriana Nanni and Alessandra Lombardi and Emanuela Scarpi and Wainer Zoli",
year = "1998",
doi = "10.1023/A:1006063412726",
language = "English",
volume = "49",
pages = "209--217",
journal = "Breast Cancer Research and Treatment",
issn = "0167-6806",
publisher = "Springer New York LLC",
number = "3",

}

TY - JOUR

T1 - Modulating effect of lonidamine on response to doxorubicin in metastatic breast cancer patients

T2 - Results front a multicenter prospective randomized trial

AU - Amadori, Dino

AU - Frassineti, Giovanni Luca

AU - De Matteis, Andrea

AU - Mustacchi, Giorgio

AU - Santoro, Antonio

AU - Cariello, Salvatore

AU - Ferrari, Massimo

AU - Nascimben, Ottorino

AU - Nanni, Oriana

AU - Lombardi, Alessandra

AU - Scarpi, Emanuela

AU - Zoli, Wainer

PY - 1998

Y1 - 1998

N2 - Previous results from our preclinical studies have shown that lonidamine (LND) can positively modulate the antiproliferative activity of doxorubicin (DOX) on breast cancer cell lines. To evaluate the effect of LND in a clinical setting, a multicenter randomized trial was carried out on patients with advanced breast cancer. From September 1991 to July 1993, 181 patients were enrolled in the trial and received an initial treatment of DOX at 75 mg/m2 for 3 cycles. The 137 patients who reached complete remission, partial remission, or stable disease were randomized to receive either DOX alone (75 mg/m2 day 1) (arm A) or DOX plus LND (600 mg orally/day) (arm B). The patients enrolled in the two arms were fairly homogeneous in terms of major clinical characteristics. Toxicity was similar in both arms except for myalgia: WHO grade ≤ 2 was observed in 57% of arm B patients. Overall response rate to DOX+LND was 50% and to DOX alone 38% in evaluable patients, and 48% vs 37% in all registered patients, as determined by an intention-to-treat analysis. The differences did not reach statistical significance. Conversely, in agreement with previous findings, we observed a significant difference in response rate in the subgroup of patients with liver metastases, regardless of the extent of hepatic involvement (DOX+LND 68% vs DOX 33%, p = 0.03). This observation makes LND an important tool in association with anthracyclines in the treatment of this subgroup of patients.

AB - Previous results from our preclinical studies have shown that lonidamine (LND) can positively modulate the antiproliferative activity of doxorubicin (DOX) on breast cancer cell lines. To evaluate the effect of LND in a clinical setting, a multicenter randomized trial was carried out on patients with advanced breast cancer. From September 1991 to July 1993, 181 patients were enrolled in the trial and received an initial treatment of DOX at 75 mg/m2 for 3 cycles. The 137 patients who reached complete remission, partial remission, or stable disease were randomized to receive either DOX alone (75 mg/m2 day 1) (arm A) or DOX plus LND (600 mg orally/day) (arm B). The patients enrolled in the two arms were fairly homogeneous in terms of major clinical characteristics. Toxicity was similar in both arms except for myalgia: WHO grade ≤ 2 was observed in 57% of arm B patients. Overall response rate to DOX+LND was 50% and to DOX alone 38% in evaluable patients, and 48% vs 37% in all registered patients, as determined by an intention-to-treat analysis. The differences did not reach statistical significance. Conversely, in agreement with previous findings, we observed a significant difference in response rate in the subgroup of patients with liver metastases, regardless of the extent of hepatic involvement (DOX+LND 68% vs DOX 33%, p = 0.03). This observation makes LND an important tool in association with anthracyclines in the treatment of this subgroup of patients.

KW - Advanced breast cancer

KW - Doxorubicin

KW - Lonidamine

UR - http://www.scopus.com/inward/record.url?scp=7344255198&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=7344255198&partnerID=8YFLogxK

U2 - 10.1023/A:1006063412726

DO - 10.1023/A:1006063412726

M3 - Article

C2 - 9776504

AN - SCOPUS:7344255198

VL - 49

SP - 209

EP - 217

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

SN - 0167-6806

IS - 3

ER -